Apr. 17 at 3:08 PM
$CRVS just got a major catalyst: Goldman Sachs initiating with a
$40 PT — that’s not noise, that’s positioning.
👉Click to view @NasdaqPulse for timely updates amid the volatility.
The narrative is clear: a leading oral player targeting a ~
$24B post-Dupixent atopic dermatitis market. If execution holds, this isn’t just another biotech — it’s a potential category disruptor.
At ~
$4B market cap, it’s now sitting right in the same arena as
$APGE and
$KYMR (~
$4B–
$7B), but with a differentiated angle that the Street is starting to price in.
This is where things get interesting: early coverage + big TAM + rerating potential = momentum fuel.
Biotech is all about perception shifts — and today, perception just changed.
Watch the follow-through. This kind of initiation can spark multi-day flows if institutions step in.
